Combinatorial treatment using bevacizumab/pemetrexed loaded core-shell silica nanoparticles for non-small cell lung cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–15. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi: 10.1038/nature25183
   PubMed Web of Science ®Google Scholar
• Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–557. doi: 10.1038/s41571-021-00501-4
   PubMed Web of Science ®Google Scholar
• Singh SS, Dahal A, Shrestha L, et al. Genotype driven therapy for non-small cell lung cancer: resistance, pan inhibitors and immunotherapy. Curr Med Chem. 2020;27(32):5274–5316. doi: 10.2174/0929867326666190222183219
   PubMed Web of Science ®Google Scholar
• Friedlaender A, Subbiah V, Russo A, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022;19(1):51–69. doi: 10.1038/s41571-021-00558-1
   PubMed Web of Science ®Google Scholar
• Passaro A, Jänne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377–391. doi: 10.1038/s43018-021-00195-8
   PubMedGoogle Scholar
• Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18(10):625–644. doi: 10.1038/s41571-021-00520-1
   PubMed Web of Science ®Google Scholar
• Jiang P, Geng L, Mao Z, et al. First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy. 2022;14(6):445–457. doi: 10.2217/imt-2021-0112
   Web of Science ®Google Scholar
• Wang J, Zhao Q, Cai L, et al. Efficacy of bevacizumab and gemcitabine in combination with cisplatin in the treatment of esophageal cancer and the effect on the incidence of adverse reactions. Biomed Res Int. 2022;2022:1–6. doi: 10.1155/2022/2317181
   Web of Science ®Google Scholar
• Nozawa K, Takatsuka D, Endo Y, et al. Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: a systematic review and meta-analysis of randomised clinical trials. Crit Rev Oncol/Hematol. 2022;174:103703. doi: 10.1016/j.critrevonc.2022.103703
   PubMed Web of Science ®Google Scholar
• Lu L, Zhan M, Li X-Y, et al. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Opin Immunol. 2022;3:118–127. doi: 10.1016/j.crimmu.2022.05.003
   Google Scholar
• Middleton G, Fletcher P, Popat S, et al. Publisher correction: the national lung matrix trial of personalised therapy in lung cancer. Nature. 2020;585(7826):E21–E21. doi: 10.1038/s41586-020-2656-3
   PubMedGoogle Scholar
• Yuan M, Huang L-L, Chen J-H, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal transduction and targeted therapy. Signal Transduct Target Ther. 2019;4(1):61. doi: 10.1038/s41392-019-0099-9
   PubMedGoogle Scholar
• Drilon A, Hellmann MD. An umbrella approach to test lung cancer therapies. Nature. 2020;583(7818):688–689. doi: 10.1038/d41586-020-02062-5
   PubMed Web of Science ®Google Scholar
• Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, et al. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017;49(3):1601520. doi: 10.1183/13993003.01520-2016
   PubMed Web of Science ®Google Scholar
• Wan R, Dong X, Chen Q, et al. Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. EClinicalMedicine. 2021;42:42. doi: 10.1016/j.eclinm.2021.101187
   Google Scholar
• Nogami N, Barlesi F, Socinski MA, et al. IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J Thorac Oncol. 2022;17(2):309–323. doi: 10.1016/j.jtho.2021.09.014
   PubMed Web of Science ®Google Scholar
• Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther. 2009;9(4):507–517. doi: 10.1517/14712590902817817
   PubMed Web of Science ®Google Scholar
• García-Fernández C, Fornaguera C, Borrós S. Nanomedicine in non-small cell lung cancer: from conventional treatments to immunotherapy. Cancers. 2020;12(6):1609. doi: 10.3390/cancers12061609
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nature Rev Mater. 2016;1(5):1–12. doi: 10.1038/natrevmats.2016.14
   Web of Science ®Google Scholar
• Kwon S, Singh RK, Perez RA, et al. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 2013;4:2041731413503357. doi: 10.1177/2041731413503357
   Google Scholar
• Tiburcius S, Krishnan K, Jose L, et al. Egg-yolk core–Shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells. Nanoscale. 2022;14(18):6830–6845. doi: 10.1039/D2NR00783E
   PubMed Web of Science ®Google Scholar
• Vinu AA, Murugesan V, Hartmann M. Adsorption of lysozyme over mesoporous molecular sieves MCM-41 and SBA-15: influence of pH and aluminum incorporation. J Phys Chem B. 2004;108(22):7323–7330. doi: 10.1021/jp037303a
   Web of Science ®Google Scholar
• Miyahara M, Vinu A, Hossain KZ, et al. Adsorption study of heme proteins on SBA-15 mesoporous silica with pore-filling models. Thin Solid Films. 2006;499(1–2):13–18. doi: 10.1016/j.tsf.2005.07.046
   Web of Science ®Google Scholar
• Ariga K, Ji Q, Hill JP, et al. Coupling of soft technology (layer-by-layer assembly) with hard materials (mesoporous solids) to give hierarchic functional structures. Soft Matter. 2009;5(19):3562–3571. doi: 10.1039/b909397d
   Web of Science ®Google Scholar
• Vinu A, Streb C, Murugesan V, et al. Adsorption of cytochrome c on new mesoporous carbon molecular sieves. J Phys Chem B. 2003;107(33):8297–8299. doi: 10.1021/jp035246f
   Web of Science ®Google Scholar
• Chandrasekar G, Vinu A, Murugesan V, et al. Adsorption of vitamin E on mesoporous silica molecular sieves. In: Čejka J, Žilková N, Nachtigall P, editors. Studies in surface science and catalysis. Vol. 158. Amsterdam, Netherlands: Elsevier; 2005. p. 1169–1176.
   Google Scholar
• Hun Kim M, Choi G, Elzatahry A, et al. Review of clay-drug hybrid materials for biomedical applications: administration routes. Clays Clay Miner. 2016;64(2):115–130. doi: 10.1346/CCMN.2016.0640204
   PubMed Web of Science ®Google Scholar
• Kumar R, Mondal K, Panda PK, et al. Core–shell nanostructures: perspectives towards drug delivery applications. J Mat Chem B. 2020;8(39):8992–9027. doi: 10.1039/D0TB01559H
   Web of Science ®Google Scholar
• Rong J, Li P, Ge Y, et al. Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction. Colloids Surf B. 2020;186:110674. doi: 10.1016/j.colsurfb.2019.110674
   PubMed Web of Science ®Google Scholar
• Almáši M, Beňová E, Zeleňák V, et al. Cytotoxicity study and influence of SBA-15 surface polarity and pH on adsorption and release properties of anticancer agent pemetrexed. Mater Sci Eng C. 2020;109:110552. doi: 10.1016/j.msec.2019.110552
   PubMed Web of Science ®Google Scholar
• Wang T, Liu Y, Wu C. Effect of paclitaxel-mesoporous silica nanoparticles with a core-shell structure on the human lung cancer cell line A549. Nanoscale Res Lett. 2017;12(1):1–8. doi: 10.1186/s11671-017-1826-1
   PubMedGoogle Scholar
• Cho N-H, Cheong T-C, Min JH, et al. A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol. 2011;6(10):675–682. doi: 10.1038/nnano.2011.149
   PubMed Web of Science ®Google Scholar
• Junginger H. Oral applications of pulsatile drug delivery. PAPERBACK APV. 1993;33:113–113.
   Google Scholar
• Streubel A, Siepmann J, Peppas N, et al. Bimodal drug release achieved with multi-layer matrix tablets: transport mechanisms and device design. J Controlled Release. 2000;69(3):455–468. doi: 10.1016/S0168-3659(00)00334-5
   PubMed Web of Science ®Google Scholar
• Radhakrishnan D, Mohanan S, Choi G, et al. The emergence of nanoporous materials in lung cancer therapy. Sci Technol Adv Mater. 2022;23(1):225–274. doi: 10.1080/14686996.2022.2052181
   PubMed Web of Science ®Google Scholar
• Sundarraj S, Thangam R, Sujitha MV, et al. Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy. Toxicol Appl Pharmacol. 2014;275(3):232–243. doi: 10.1016/j.taap.2014.01.012
   PubMed Web of Science ®Google Scholar
• Tiburcius S, Krishnan K, Patel V, et al. Triple surfactant assisted synthesis of novel core-shell mesoporous silica nanoparticles with high surface area for drug delivery for prostate cancer. Bull Chem Soc Jpn. 2022;95(2):331–340. doi: 10.1246/bcsj.20210428
   Web of Science ®Google Scholar
• Zhang L, Song F, Wu Y, et al. A novel amino and carboxyl functionalised mesoporous silica as an efficient adsorbent for nickel (II). J Chem Eng Data. 2018;64(1):176–188. doi: 10.1021/acs.jced.8b00689
   Web of Science ®Google Scholar
• Cauda V, Schlossbauer A, Kecht J, et al. Multiple core− Shell functionalised colloidal mesoporous silica nanoparticles. J Am Chem Soc. 2009;131(32):11361–11370. doi: 10.1021/ja809346n
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guo J, Zhang X-L, et al. Antibody fragment-armed mesoporous silica nanoparticles for the targeted delivery of bevacizumab in ovarian cancer cells. Int J Pharmaceut. 2015;496(2):1026–1033. doi: 10.1016/j.ijpharm.2015.10.080
   PubMed Web of Science ®Google Scholar
• Malhotra B, Evans T, Weiss J, et al. Carboplatin/Pemetrexed/Bevacizumab in the treatment of patients with advanced non–small-cell lung cancer: a single-institution experience. Clin Lung Cancer. 2010;11(3):192–197. doi: 10.3816/CLC.2010.n.025
   PubMed Web of Science ®Google Scholar
• Stefanou D, Stamatopoulou S, Sakellaropoulou A, et al. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett. 2016;12(6):4635–4642. doi: 10.3892/ol.2016.5268
   PubMed Web of Science ®Google Scholar
• Yan J, Zhong N, Liu G, et al. Usp9x-and noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014;5(7):e1316–e1316. doi: 10.1038/cddis.2014.281
   PubMedGoogle Scholar
• Pangeni R, Choi JU, Panthi VK, et al. Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. Int J Nanomed. 2018;13:3329–3351. doi: 10.2147/IJN.S167958
   PubMed Web of Science ®Google Scholar
• Spitzmüller L, Nitschke F, Rudolph B, et al. Dissolution control and stability improvement of silica nanoparticles in aqueous media. J Nanopart Res. 2023;25(3):40. doi: 10.1007/s11051-023-05688-4
   Web of Science ®Google Scholar
• Zhang D, Wei L, Zhong M, et al. Correction: the morphology and surface charge-dependent cellular uptake efficiency of upconversion nanostructures revealed by single-particle optical microscopy. Chem Sci. 2022;13(12):3610–3610. doi: 10.1039/D2SC90037H
   PubMed Web of Science ®Google Scholar
• Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed. 2012;5577–5591. doi: 10.2147/IJN.S36111
   PubMed Web of Science ®Google Scholar
• Chen K-C, Yang T-Y, Wu C-C, et al. Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway. PLoS One. 2014;9(5):e97888. doi: 10.1371/journal.pone.0097888
   PubMed Web of Science ®Google Scholar